An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Aficamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions; Registrational
- Sponsors Corxel Pharmaceuticals
Most Recent Events
- 27 Oct 2024 According to a CORXEL media release, Ji Xing Pharmaceuticals name changed to CORXEL.
- 04 Mar 2024 Status changed from not yet recruiting to recruiting.
- 31 Oct 2023 Planned number of patients changed to 44.